CytomX Therapeutics (CTMX) Non-Current Deffered Revenue (2014 - 2026)
CytomX Therapeutics (CTMX) posted Non-Current Deffered Revenue of $979000.0 for Q1 2026, down 38.43% on a QoQ basis from $1.6 million in Q4 2025, and down 93.96% year-over-year from $16.2 million in Q1 2025.
CytomX Therapeutics (CTMX) Non-Current Deffered Revenue (2014 - 2026) Analysis & Trends
CytomX Therapeutics' Non-Current Deffered Revenue history runs 13 years deep, the most recent figure standing at $979000.0 for Q1 2026.
- Quarterly Non-Current Deffered Revenue fell 93.96% year-over-year to $979000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $979000.0 (down 93.96% YoY) and the FY2025 annual result came in at $1.6 million, down 94.08% from the prior year.
- Non-Current Deffered Revenue was $979000.0 for Q1 2026 at CytomX Therapeutics, down from $1.6 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $222.1 million in Q1 2022 and bottomed at $979000.0 in Q1 2026.
- A 5-year average of $85.7 million and a median of $59.7 million in 2024 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue retreated 17.06% — and 2025, when it slumped 94.08%.
- CytomX Therapeutics' Non-Current Deffered Revenue stood at $180.1 million in 2022, then tumbled by 55.54% to $80.0 million in 2023, then tumbled by 66.44% to $26.9 million in 2024, then slumped by 94.08% to $1.6 million in 2025, then sank by 38.43% to $979000.0 in 2026.
- Business Quant data shows CTMX's Non-Current Deffered Revenue at $979000.0 in Q1 2026, $1.6 million in Q4 2025, and $5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - | 979,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 979,000.00 |
| Dec 31, 2025 | 1.59 Mn |
| Sep 30, 2025 | 5.54 Mn |
| Jun 30, 2025 | 10.24 Mn |
| Mar 31, 2025 | 16.21 Mn |
| Dec 31, 2024 | 26.86 Mn |
| Sep 30, 2024 | 33.56 Mn |
| Jun 30, 2024 | 36.71 Mn |
| Mar 31, 2024 | 59.74 Mn |
| Dec 31, 2023 | 80.05 Mn |
| Sep 30, 2023 | 112.26 Mn |
| Jun 30, 2023 | 140.87 Mn |
| Mar 31, 2023 | 157.13 Mn |
| Dec 31, 2022 | 180.06 Mn |
| Sep 30, 2022 | 168.33 Mn |
| Jun 30, 2022 | 203.91 Mn |
| Mar 31, 2022 | 222.09 Mn |
| Dec 31, 2021 | 243.94 Mn |
| Sep 30, 2021 | 254.26 Mn |
| Jun 30, 2021 | 264.09 Mn |